Chemclin Diagnostics(SH:688468) Xin Lang Zheng Quan·2025-10-30 11:15Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]